RPRX:NSC-Repros Therapeutics Inc. (USD)

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing

USD 26.36

Change

+0.15 (+0.57)%

Market Cap

USD 0.05B

Volume

2.78M

Analyst Target

USD 52.29
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Repros Therapeutics Inc is a development stage biopharmaceutical company. The Company is engaged in the development of new drugs to treat hormonal and reproductive system disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-11 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-11.72 (-2.34%)

USD 121.60B
REGN Regeneron Pharmaceuticals Inc

-4.68 (-0.57%)

USD 92.70B
ALNY Alnylam Pharmaceuticals Inc

-10.87 (-3.88%)

USD 36.09B
ARGX argenx NV ADR

+5.01 (+0.85%)

USD 35.78B
BGNE BeiGene Ltd

-11.40 (-5.56%)

USD 22.85B
MRNA Moderna Inc

+0.72 (+1.68%)

USD 21.00B
UTHR United Therapeutics Corporatio..

+0.43 (+0.11%)

USD 16.70B
INCY Incyte Corporation

-0.95 (-1.17%)

USD 14.67B
SMMT Summit Therapeutics PLC

-1.01 (-4.64%)

USD 13.75B
PCVX Vaxcyte Inc

-4.26 (-4.11%)

USD 13.28B

ETFs Containing RPRX

ROYL:AU BetaShares Global Royalti.. 6.21 % 0.00 %

-0.16 (0%)

N/A
ROYA 4.80 % 0.00 %

N/A

N/A
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

-1.00 (0%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.16% 55% F 38% F
Dividend Return 2.24% 50% F 43% F
Total Return -3.92% 56% F 39% F
Trailing 12 Months  
Capital Gain -2.77% 47% F 33% F
Dividend Return 3.06% 50% F 43% F
Total Return 0.30% 48% F 34% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -9.33% 34% F 22% F
Dividend Return -7.89% 36% F 23% F
Total Return 1.44% 17% F 35% F
Risk Return Profile  
Volatility (Standard Deviation) 12.80% 99% N/A 85% B
Risk Adjusted Return -61.63% 18% F 11% F
Market Capitalization 0.05B 99% N/A 95% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.13 32% 51%
Price/Book Ratio 1.88 58% 50%
Price / Cash Flow Ratio 5.31 6% 40%
Price/Free Cash Flow Ratio 14.18 5% 26%
Management Effectiveness  
Return on Equity 10.53% 96% 78%
Return on Invested Capital 7.30% 85% 72%
Return on Assets 3.45% 96% 80%
Debt to Equity Ratio 94.01% 22% 25%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector